GlassScriptPhysician profile
Steven M Brown
NPI 1659459873
$2,079.63
in general payments reported to CMS, 2019-2025
20 companies · $256 in 2025
The $256 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $621 · 2020: $13.00 · 2021: $261 · 2022: $458 · 2023: $251 · 2024: $220 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $726.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $576.97 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $208.76 | 2019-2025 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $207.25 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $197.72 | 2019-2025 | Airsupra, Breztri |
| Amgen INC. | $176.89 | 2019-2023 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.12 | 2019-2025 | Jardiance |
| Stryker Corporation | $93.48 | 2025 | Flowtriever, Artix Mt, Clottriever Bold Catheter |
| Bayer Healthcare Pharmaceuticals INC. | $80.31 | 2022-2024 | |
| Astellas Pharma US INC | $76.09 | 2019 | |
| Pfizer INC. | $52.81 | 2023 | |
| Idorsia Pharmaceuticals US INC | $43.31 | 2023-2024 | Quviviq |
| Abbvie INC. | $38.83 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $36.80 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $36.28 | 2024 | Gemtesa |
| Dynavax Technologies Corporation | $32.57 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $26.30 | 2021 | |
| Abbott Laboratories | $22.41 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.08 | 2022 | |
| Merck Sharp & Dohme LLC | $19.48 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $19.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.